Stock Track | Keros Therapeutics Soars 6.89% Following Analyst Upgrades and Buy Ratings

Stock Track12-13

Keros Therapeutics, Inc. (KROS) witnessed a significant surge of 6.89% in its stock price during Friday's intraday trading session. This rally was fueled by positive analyst coverage from prominent firms.

Scotiabank analyst Greg Harrison reiterated a Buy rating on Keros Therapeutics and set a price target of $44.00, reflecting the potential for substantial upside from the current levels. Additionally, Truist Financial analyst Srikripa Devarakonda also assigned a Buy rating to the stock, further boosting investor confidence.

The positive analyst sentiment appears to be a driving force behind the stock's impressive performance today. Investors are encouraged by the optimistic outlook from analysts, potentially signaling promising prospects for Keros Therapeutics in the near future.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1195090868?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-12-13 22:32","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1195090868","market":"hk","top_or_hot":-1,"title":"Stock Track | Keros Therapeutics Soars 6.89% Following Analyst Upgrades and Buy Ratings","media":"Stock Track","content":"<p>Keros Therapeutics, Inc. (KROS) witnessed a significant surge of 6.89% in its stock price during Friday's intraday trading session. This rally was fueled by positive analyst coverage from prominent firms.</p>\n\n<p>Scotiabank analyst Greg Harrison reiterated a Buy rating on Keros Therapeutics and set a price target of $44.00, reflecting the potential for substantial upside from the current levels. Additionally, Truist Financial analyst Srikripa Devarakonda also assigned a Buy rating to the stock, further boosting investor confidence.</p>\n\n<p>The positive analyst sentiment appears to be a driving force behind the stock's impressive performance today. Investors are encouraged by the optimistic outlook from analysts, potentially signaling promising prospects for Keros Therapeutics in the near future.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Keros Therapeutics Soars 6.89% Following Analyst Upgrades and Buy Ratings</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Keros Therapeutics Soars 6.89% Following Analyst Upgrades and Buy Ratings\n</h2>\n\n<h4 class=\"meta\">\n\n2024-12-13 22:32 北京时间&nbsp;&nbsp;&nbsp;<strong>Stock Track</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Keros Therapeutics, Inc. (KROS) witnessed a significant surge of 6.89% in its stock price during Friday's intraday trading session. This rally was fueled by positive analyst coverage from prominent ...</p>\n\n<a href=\"\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"KROS","symbol_name":"Keros Therapeutics, Inc.","start_time":0,"source_url":"","article_id":"1195090868","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1195090868","pubTimestamp":1734100338,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Keros Therapeutics, Inc.  witnessed a significant surge of 6.89% in its stock price during Friday's intraday trading session. This rally was fueled by positive analyst coverage from prominent firms.Scotiabank analyst Greg Harrison reiterated a Buy rating on Keros Therapeutics and set a price target of $44.00, reflecting the potential for substantial upside from the current levels. Additionally, Truist Financial analyst Srikripa Devarakonda also assigned a Buy rating to the stock, further boostin","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"KROS":"Keros Therapeutics, Inc."},"translate_title":"分析师上调和买入评级后，Keros Therapeutics股价飙升6.89%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"KROS":1},"content_text":"Keros Therapeutics, Inc. (KROS) witnessed a significant surge of 6.89% in its stock price during Friday's intraday trading session. This rally was fueled by positive analyst coverage from prominent firms.\nScotiabank analyst Greg Harrison reiterated a Buy rating on Keros Therapeutics and set a price target of $44.00, reflecting the potential for substantial upside from the current levels. Additionally, Truist Financial analyst Srikripa Devarakonda also assigned a Buy rating to the stock, further boosting investor confidence.\nThe positive analyst sentiment appears to be a driving force behind the stock's impressive performance today. Investors are encouraged by the optimistic outlook from analysts, potentially signaling promising prospects for Keros Therapeutics in the near future.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1195090868"}